Stay updated with breaking news from Immatic Actengine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company to host conference calltoday, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target dose in different solid cancers in an interim clinical update in Phase 1a and Phase
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics' proprietary CD8aß co-receptor engaging functional CD4 and CD8 T cells directed against PRAME Preclinical data with IMA203CD8
The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab1, a PD-1 immune checkpoint inhibitor